Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Jasper Summit Research LLC

Neither a doctor nor a teaching hospital

Research payments

$702,342

105 payments

Through program year 2025, Jasper Summit Research LLC is reported as receiving $702,342 in research payments, across 105 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $17,472 6
2024 Research $128,831 17
2023 Research $164,584 26
2022 Research $193,212 32
2021 Research $56,603 7
2020 Research $103,721 13
2019 Research $37,920 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $273,586 33 payments
  2. AstraZeneca Pharmaceuticals LP $103,643 15 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $99,407 4 payments
  4. Sanofi US Services Inc. $83,009 22 payments
  5. Hoffmann-La Roche Limited $72,836 10 payments
  6. GlaxoSmithKline, LLC. $34,489 12 payments
  7. United Therapeutics Corporation $20,171 5 payments
  8. Chiesi USA, Inc. $13,700 3 payments
  9. Mylan Specialty L.P. $1,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. PH Iib of Astegolimab in COPD $196,968 23 payments
  2. Ph III OLE of Astegolimab in COPD $149,454 20 payments
  3. Tio & Olo versus PBO stratified by PIFR $87,757 2 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $55,509 19 payments
  5. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $38,108 2 payments
  6. AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD which enables the virus to bind to receptors on human cells. By targeting this region of the virus spike protein antibodies can block the virus attachment to human cells and therefore is expected to block infection. Amino acid substitutions have been introduced into the antibodies to both extend their half lives which should prolong their potential prophylactic benefit and decrease $31,587 6 payments
  7. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $25,239 7 payments
  8. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $20,171 5 payments
  9. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $17,100 1 payment
  10. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $16,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record